Prostate Cancer Low Risk
Reviewed by Oncology Team, HealOnco | Last updated: 2026-04
What Low Risk Means
Stage T1–T2a, Gleason 6, PSA <10 ng/mL
Treatment Approach for Low Risk
Active surveillance or definitive therapy (RARP or radiation). Discuss 10-year life expectancy; if >15 years, consider treatment to prevent future progression.
Survival Rates and Prognosis
The 5-year survival rate for prostate cancer at Low Risk is approximately 98%+ (10-yr: 95%). Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Very Low Risk | 99%+ (10-yr: 98%+) | Active surveillance preferred. Annual PSA, DRE, repeat biopsy in 1–2… |
| Intermediate Risk | 95% (10-yr: 88%–92%) | Definitive therapy: RARP with or without pelvic lymph node dissection, or EBRT… |
| High Risk | 88%–93% (10-yr: 75%–85%) | Definitive therapy + ADT. EBRT – 24–36 months ADT preferred if fit…. |
| Very High Risk | 70%–85% (10-yr: 55%–75%) | Aggressive systemic therapy. EBRT – 36+ months ADT with or without… |
| Metastatic Hormone-Sensitive (mHSPC) | 40%–60% (10-yr: 10%–25%) | Upfront ADT + docetaxel (STAMPEDE/CHAARTED trials showed docetaxel improves… |
| Metastatic Castration-Resistant (mCRPC) | 15%–30% (10-yr: <10%) | Sequence of hormone therapies (abiraterone, enzalutamide, apalutamide) or… |
Prostate Cancer Treatment in Top Cities
Diagnosed with Low Risk Prostate Cancer?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free Consultation